SCHEMBL23536145

SCHEMBL23536145

Cc1cc(S(N)(=O)=O)ccc1S(N)(=O)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDIA6 Q15084 1/20 0.53
CA2 P00918 11/20 0.52
CA1 P00915 10/20 0.52
CA9 Q16790 10/20 0.52
CA12 O43570 8/20 0.52
CA6 P23280 5/20 0.52
CA5A P35218 5/20 0.52
CA7 P43166 5/20 0.52
CA5B Q9Y2D0 5/20 0.52
CA3 P07451 1/20 0.52
LMNA P02545 2/20 0.46
CA4 P22748 4/20 0.45
CA14 Q9ULX7 4/20 0.45
APEX1 P27695 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2228430 0.88 L3MBTL1 (0.50) PDIA6CA2CA1CA9CA12
SCHEMBL14323194 0.83 PDIA6 (0.46) PDIA6CA2CA1CA9CA12
SCHEMBL1925948 0.83 CA2 (0.52) CA2CA1CA9CA12CA6
SCHEMBL233320 0.82 LMNA (0.61) CA2CA1CA9CA12CA6
SCHEMBL29365636 0.82 LMNA (0.61) CA2CA1CA9CA12CA6
SCHEMBL11320791 0.81 CA2 (0.46) PDIA6CA2CA1CA9CA12
SCHEMBL11332582 0.81 HTR6 (0.55) PDIA6CA2CA1CA9CA12
SCHEMBL30266645 0.80 PDIA6 (0.55) PDIA6CA2CA1CA9CA12
SCHEMBL5795116 0.80 PDIA6 (0.55) PDIA6CA2CA1CA9CA12
SCHEMBL11319750 0.80 GAA (0.49) PDIA6CA2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2024-06-13 US disclosed
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 PDIA6 3125/4885CA2 294/4885CA1 1974/4885
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF PACSIN2, TPX2, PRSS12 PDIA6 156/4885CA2 3857/4885CA1 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.